DCM
SPRO icon

Dupont Capital Management’s Spero Therapeutics SPRO Stock Holding History

Dupont Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-37,421
Closed -$302K – 1412
2020
Q1 		$302K Buy
+37,421
New +$330K 0.01% 860

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dupont Capital Management's SPRO Position: Q2 2020 in Review

Dupont Capital Management sold out of Spero Therapeutics (SPRO) in Q2 2020, closing a stake of 37,421 shares — an estimated $302K sold.

Dupont Capital Management first reported a position in SPRO in Q1 2020 and held it in 1 quarter. The position peaked at $302K in Q1 2020. 80 funds tracked by Wall St. Rank hold SPRO as of Q2 2020.

  • Dupont Capital Management reported no remaining Spero Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Dupont Capital Management sold 37,421 Spero Therapeutics shares in Q2 2020, an estimated $302K.
  • Dupont Capital Management first reported a position in Spero Therapeutics in Q1 2020 and held it in 1 quarter.
  • Dupont Capital Management's Spero Therapeutics position peaked at $302K in Q1 2020.
  • 80 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2020.

Based on Dupont Capital Management's 13F filing for Q2 2020, filed 24 Jul 2020.